Метаболический синдром и почки: патогенетически обоснованные нефропротекция и снижение сердечно-сосудистого риска
https://doi.org/10.18705/1607-419X-2018-24-3-369-378
Аннотация
Ключевые слова
Об авторах
С. В. НедогодаРоссия
доктор медицинских наук, профессор, заведующий кафедрой терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
Е. В. Чумачек
Россия
кандидат медицинских наук, ассистент кафедры терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
В. В. Цома
Россия
кандидат медицинских наук, ассистент кафедры терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
А. С. Саласюк
Россия
кандидат медицинских наук, ассистент кафедры терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
В. О. Смирнова
Россия
аспирант кафедры терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
В. Ю. Хрипаева
Россия
аспирант кафедры терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
Р. В. Палашкин
Россия
аспирант кафедры терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
Е. А. Попова
Россия
аспирант кафедры терапии и эндокринологии факультета усовершенствования врачей,
ул. Циолковского, 1, Волгоград, 400001
Список литературы
1. World Health Organization, Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus, 1999.
2. Chen J, Muntner P, Hamm LL, Jones D W, Batuman V, Fonseca V et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–74.
3. Chen J, Gu D, Chen CS, Wu X, Hamm L L, Muntner P et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22(4):1100–6.
4. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48 (3):383–391.
5. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134–2140.
6. Maggio A, Wacker J, Montecucco F, Galan K, Pelli G, Mach F et al. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr. 2012;161(6):1022– 1027.
7. Maffei M, Halaas J, Ravussin E, Pratley R, Lee G, Zhang Y et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNAin obese and weight-reduced subjects. Nat Med. 1995;1(11):1155–1161.
8. Lönnqvist F, Nordfors L, Jansson M, Thörne A, Schalling M, Arner P. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest. 1997;99(10):2398–2404.
9. Meyer C, Robson D, Rackovsky N, NadkarniV, Gerich J. Role of the kidney in human leptin metabolism. Am J Physiol. 1997;273 (5 Pt 1): E903–E907.
10. Montani J, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes. 2002;26(Suppl 2): S28–S38.
11. Kramer H, Saranathan A, Luke A, Durazo-Arvizu R, Guichan C, Hou S et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17 (5):1453–1459.
12. Martinez Cantarin M, Waldman SA, Doria C, Frank AM, Maley WR, Ramirez CB et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int. 2013;83(3):487–494.
13. MenonV, Li L, WangX, Greene T, BalakrishnanV, Madero M et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(9):2599–2606.
14. Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di Paola R et al. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One. 2012;7(6): e38414.
15. Agrawal S, Shlipak MG, Kramer H, Jain A, Herrington DM. The association of chronic kidney disease and metabolic syndrome with incident cardiovascular events: multiethnic study of atherosclerosis. Cardiol Res Pract. 2012;2012:806102. doi:10.1155/2012/806102
16. Kunimura A, Amano T, Uetani T, Harada K, Yoshida T, Suzuki A et al. Prognostic impact of concurrence of metabolic syndrome and chronic kidney disease in patients undergoing coronary intervention: involvement of coronary plaque composition. J Cardiol. 2013;61(3):189–195.
17. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley CM, Coombes JS et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton). 2007;12(4):391–398.
18. Kim CS, Choi JS, Bae EH, Ma SK, Ahn YK, Jeong MH et al.; Korea Acute Myocardial Infarction Registry Investigators. Association of metabolic syndrome and renal insufficiency with clinical outcome in acute myocardial infarction. Metabolism. 2013;62(5):669–676.
19. Xu H, Huang X, Arnlöv J, Cederholm T, Stenvinkel P, Lindholm B et al. Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. Clin J Am Soc Nephrol. 2014;9(4):690–697.
20. Chan DT, Watts GF, Irish AB, Ooi EM, Dogra GK. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease. Am J Hypertens. 2013;26(9):1155–1161.
21. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol. 2013;305(12): F1629–F1636.
22. Axelsson J, Stenvinkel P. Role of fat mass and adipokinesin chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17 (1):25–31.
23. RaikouVD, Gavriil S. Metabolic syndrome and chronic renal disease. Diseases. 2018;6(1):12. doi:10.3390/diseases6010012
24. Khaled N, Brent M. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:421–435. doi:10.2147/DMSO.S45183
25. Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne D. Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int. 1998;18(1):34–40.
26. Merabet E, Dagogo-Jack S, Coyne D, Klein S, Santiago J, Hmiel S et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab. 1997;82(3):847–850.
27. Sharma K, Considine R, Michael B, Dunn S, Weisberg L, Kurnik B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997;51(6):1980– 1985.
28. Axelsson J, Bergsten A, Qureshi A, Heimbürger O, Bárány P, Lönnqvist F et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006;69(3):596–604.
29. Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di Paola R et al. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One. 2012;7(6): e38414.
30. Malyszko J, Malyszko J, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc. 2009;41 (1):150–153.
31. Doumatey A, Zhou J, Huang H, Adeleye J, Balogun W, Fasanmade O et al. Circulating adiponectin is associated with renal function independent of age and serum lipids in West Africans. Int J Nephrol. 2012;2012:730920. doi:10.1155/2012/730920. doi: 10.1155/2012/730920
32. Sharma K, Ramachandrarao S, Qui G, Usui H, Zhu Y, Dunn S et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118(5):1645–1656.
33. Недогода С.В. Ожирение в практике терапевта. М.: Эксмо-Пресс, 2017. 304 с. [Nedogoda SV. Obesity in therapeutical practice.M.: Eksmo-Press, 2017. 304 p. In Russian].
34. London GM, Asmar RG, O’Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/ indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43(1):92–99.
35. Карпов Ю. А., Деев А.Д. от имени врачей — участников исследования ПРИВИЛЕГИЯ. Исследование ПРИВИЛЕГИЯ — Престариум В лечении артериальной гипЕртонии: антиГИпертензивнаЯ эффективность и безопасность в сравнении с эналаприлом. Кардиология. 2007;7:35–40. [Karpov IuA, Deev AD. Participants of the PRIVILEGIYA Study. PRIVILEGIYA (Privilige) Study — Prestarium in the treatment of arterial hypertension: antihypertensive efficacy and safety in comparison with enalapril. Kardiologiia. 2007;47:35–40. In Russian].
36. Ionescu DD. PREFER Investigators. Antihypertensive efficacy of perindopril 5–10 mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig. 2009;29(12):767–776.
37. Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol. 1996;23(8): S30–32.
38. Koz C, Baysan O, Yokusoglu M¸ Uzun M, Yildirim M, Hasimi A et al. The effects of perindopril on aortic elasticity and inflammatory markersin hypertensive patients. Med Sci Monit. 2009;15(7): PI 41–45.
39. Nedogoda S, Ledyaeva AA, Chumachok EV, Tsoma VV, Mazina G, Salasyuk AS et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013,33(8):553–561.
40. The Scientific Committee of the PERTINENT Sub-Study on behalf of the EUROPA-PERTINENT Investigators. PERTINENTperindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther. 2003;17(1):83–91.
41. Tropeano A, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48 (1):80–86.
42. Недогода С.В., Смирнова В.О., Хрипаева В.Ю., Палашкин Р. В., Ледяева А. А., Чумачек Е. В. и др. Возможности индапамида в ангиопротекции у пациентов с метаболическим синдромом после терапии тиазидсодержащими комбинациями. Сердце: журнал для практикующих врачей. 2016;15(3):193–197. doi:10.18087/rhj.2016.3.2245 [Nedogoda SV, Smirnova VO, Hripaeva VJu, Palashkin RV, Ledyaeva AA, Chumachеk EV et al. Angioprotective possibilities of indapamide in patients with metabolic syndrome after thiazide-based combinations therapy. Russian Heart Journal. 2016;15 (3):193– 197. doi:10.18087/rhj.2016.3.2245 In Russian].
43. Недогода С.В., Ледяева А.А., Чумачек Е.В., Цома В.В., Мазина Г.Г., Саласюк А.С. и др. Сравнительная эффективность периндоприла А и лозартана у пациентов с артериальной гипертензией и ожирением. Российский кардиологический журнал. 2012;1(93):63–69. [Nedogoda SV, Ledyaeva AA, Chumachek EV, Tsoma VV, Mazina GG, Salasyuk AS et al. Comparative effectiveness of perindopril A and losartan in patients with arterial hypertension and obesity. Rus J Cardiol. 2012;1(93):63–69. In Russian].
44. Недогода С.В., Чумачек Е.В., Ледяева А.А., Цома В.В., Саласюк А.С., Смирнова В.О. и др. Оптимизация контроля артериального давления, органопротекции и метаболических нарушений с помощью фиксированной комбинации периндоприла и индапамида у пациентов с артериальной гипертензией. Кардиология. 2017;2:5–11. doi:10.18565/cardio.2017.2.5- 11 [Nedogoda SV, Chumachek EV, Ledyaeva AA, Tsoma VV, Salasyuk AS, Smirnova VO et al. Optimization of blood pressure control, metabolic disorders and target organs protection with perindopril + indapamide fixed combination in treated hypertensive patients. Kardiologiia. 2017;2:5–11. doi:10.18565/cardio.2017.2.5- 11 In Russian].
45. Недогода С.В. Нефропротекция при сахарном диабете 2 го типа: Уроки исследования ADVANCE. Фарматека. 2011;14:40–43. [Nedogoda SV. Renoprotection in type 2 diabetes mellitus patients: results of the ADVANCE study. Pharmateca. 2011;14:40–43. In Russian].
46. Dahlöf B, Gosse P, Guéret P. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005;23(11):2063–70.
Рецензия
Для цитирования:
Недогода С.В., Чумачек Е.В., Цома В.В., Саласюк А.С., Смирнова В.О., Хрипаева В.Ю., Палашкин Р.В., Попова Е.А. Метаболический синдром и почки: патогенетически обоснованные нефропротекция и снижение сердечно-сосудистого риска. Артериальная гипертензия. 2018;24(3):369-378. https://doi.org/10.18705/1607-419X-2018-24-3-369-378
For citation:
Nedogoda S.V., Chumachek E.V., Tsoma V.V., Salasyuk A.S., Smirnova V.O., Hripaeva V.J., Palashkin R.V., Popova E.A. Metabolic syndrome and kidney: nephroprotection and reduction of cardiovascular risk. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2018;24(3):369-378. (In Russ.) https://doi.org/10.18705/1607-419X-2018-24-3-369-378